Pfizer’s Ibrance® in Combination With Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 Patina Study in Patients With Hr+, Her2+ Metastatic Breast Cancer
辉瑞的Ibrance®与标准治疗方案联合使用,在HR+、Her2+转移性乳腺癌患者的3期Patina研究中,延长了中位无进展生存期超过15个月。